Plant Name: Crinum asiaticum
Taxonomic Information:
Plant ID: NPO9927
Plant Latin Name: Crinum asiaticum
Taxonomy Genus: Crinum
Taxonomy Family: Amaryllidaceae
Plant External Links:
NCBI TaxonomyDB:
205937
Plant-of-the-World-Online:
63796-1
Used in Medicines:
Country/Region:
Thailand; Australia; India; Indonesia; ChinaTraditional Medicine System:
Indian Folk; TCM; Unani; Ayurveda; SiddhaMedicinal Functions:
Emetic; Poultice
Geographical Distribution:
Madagascar; Bangladesh; Vanuatu; Cambodia; Bahamas; Laos; Australia; Cuba; Papua New Guinea; United States; China; Thailand; Dominican Republic; Maldives; Philippines; Indonesia; New Caledonia; Mauritius; Trinidad and Tobago; Vietnam; Haiti; Jamaica; Seychelles; Myanmar; Mexico; South Africa; India; Sri Lanka; Japan; Taiwan; Fiji
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PTPN1; | |
| ACHE; BCHE; | |
| TDP1; HPGD; HSD17B10; ALDH1A1; | |
| TOP1; | |
| MAPK1; | |
| CA2; CA1; CA12; CA9; CA7; CA3; CA14; CA5B; CA5A; CA6; | |
| ESR2; | |
| KDM4E; | |
| MMP9; MMP1; MMP2; | |
| NFKB1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Isomerase | TOP1 | DNA topoisomerase I | P11387 | CHEMBL1781 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.112E-12 | 5.750E-09 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, ESR2, MMP1, MMP2, MMP9, PTPN1 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.061E-07 | 1.540E-04 | BCHE, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.012E-26 | 6.559E-22 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 2.176E-06 | 2.494E-03 | ACHE, BCHE |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 4.596E-06 | 5.004E-03 | HPGD, MMP2, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.281E-06 | 5.475E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.523E-06 | 6.176E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.729E-06 | 6.732E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.329E-05 | 9.650E-03 | CYP1A2, MAPK1, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.303E-05 | 9.650E-03 | CYP1A2, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.425E-20 | 2.640E-16 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.929E-19 | 4.861E-15 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.375E-25 | 1.774E-23 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA7, CA6, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 3.478E-07 | 2.243E-05 | MMP1, MMP2, MAPK1, MMP9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.220E-05 | 5.245E-04 | MMP2, MAPK1, MMP9, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.409E-04 | 4.440E-03 | MMP1, MMP2, MAPK1, MMP9, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.528E-04 | 3.286E-03 | MAPK1, NFKB1, ESR2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.016E-05 | 2.585E-03 | CYP1A2, CYP3A4, CYP19A1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.127E-04 | 2.908E-03 | CYP1A2, ALDH1A1, CYP3A4 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 4.152E-04 | 6.695E-03 | MMP2, MAPK1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 5.330E-04 | 7.639E-03 | MAPK1, MMP9, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 8.044E-04 | 1.038E-02 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | NFKB1; ACHE; MMP9; MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP9; MMP2; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
